The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT)
Authors' conclusion
We have characterised the metabolomic effects of an integrated weight management programme previously shown to deliver weight loss and diabetes remission. A large proportion of the metabolome appears to be modifiable. Patterns of change were largely and strikingly opposite to perturbances previously documented with the development of type 2 diabetes.
Study context
- Population
- Individuals with T2D in DiRECT; fasted serum samples at baseline and 12 months574 serum samples
- Participants
- 298 individuals
- Comparison
- Weight management programme vs best-practice care
- Primary endpoint
- Effect of the intervention on metabolite levels
- Follow-up
- 12 months
Methodological detailscluster, primary care practices randomised 1:1, untargeted MS and targeted 1H-NMR metabolomics
- Cluster
- Primary care practices randomised 1:1
- Untargeted MS and targeted 1H-NMR metabolomics
Primary result
As reported in the abstract
Metabolite levels
- Decreases in branched-chain amino acids, sugars and LDL triglycerides associated with the intervention
- Holm-corrected p<0.05
- Increases in sphingolipids, plasmalogens and fatty acid metabolism–related metabolites associated with the intervention
- Holm-corrected p<0.05
Further findings
Remission vs no remission among those losing >9 kg · baseline to 12 months
- Greater reductions in glucose, fructose and mannose with diabetes remission vs no remission
Original publication
The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiRECT). Diabetologia. Published 25 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →